Melanoma
Conditions
Brief summary
To determine the safety and efficacy of the combination of HDI and anti-CTLA-4 monoclonal antibody for patients with recurrent inoperable stage III or stage IV melanoma.
Detailed description
Immunity to melanoma appears to be central to disease control in the adjuvant and advanced disease settings. Spontaneous regression has been reported in melanoma, suggesting a role for host immunity, indirectly supported by the presence of lymphoid infiltrates at primary melanoma associated with tumor regression.
Interventions
DRUGAnti-CTLA4 monoclonal antibody and HDI
One course of therapy consists of three cycles (1 cycle=28days). Anti-CTLA4 monoclonal antibody (15 mg/kg i.v.) will be given during the first cycle only. HDI will be given all three cycles - cycle 1: 20 MU/m2 i.v. on days 0, 1, 2, 3, 4 a week (MTWRF) for 4 weeks; cycle 2: 10 MU/m2 s.c. 3 days a week (MWF) for 4 weeks; and cycle 3: 10 MU/m2 s.c. 3 days a week (MWF) for 4 weeks. Response assessment will be carried out at day 56 and day 84. Every patient will receive 3 cycles regardless of response status after the first 2 cycles. However, a patient may be taken off therapy in the event of clinical progression at the discretion of the treating physician. Patients without evidence for disease progression after 3 cycles may be offered additional cycles two weeks after completion of the third cycle. Therapy will continue for a maximum of 12 months.
Sponsors
Pfizer
Ahmad Tarhini
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients must have a written informed consent obtained prior to the initiation of study procedures. * Male and female subjects greater than or equal to 18 years of age. * Patients must have histologically confirmed recurrent stage III or stage IV melanoma (AJCC 6th edition classification). Cutaneous melanoma, ocular or mucosal melanoma will be eligible. * Patients must have measurable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST). Baseline measurements must be obtained within 4 weeks prior to initiating therapy. * Patients must have adequate hematologic, renal, and liver function as evidenced by the following (within 4 weeks prior to starting the study drugs): * WBC greater than or equal to 3,000/mm3 * Lymphocytes greater than or equal to 1,000/mm3 * Platelets greater than or equal to 100,000/mm3 * Serum Creatinine less than or equal to 1.5 x upper limit of normal (ULN) * Serum Bilirubin less than or equal to 1.5 x ULN * Serum AST/ALT less than or equal to 2.5 x ULN * Serum LDH less than or equal to 2.0 x ULN * APTT less than \< 40 s * Patients must have fully recovered from any effects of major surgery, and be free of significant detectable infection. * Patients must not have received any chemotherapy, hormonal therapy, radiotherapy, or biological therapy within the preceding 4 weeks. * Patients must not have previous therapy with Anti-CTLA4 monoclonal antibodies (including CP-675,206 and MDX-010). Previous therapy with Interferon-alfa 2b in the adjuvant or metastatic setting is allowed. Previous therapy with other biological agents (including vaccines and GM-CSF) is allowed. * Patients must have ECOG performance status of 0 or 1. * Patients must not have autoimmune disorders (except vitiligo). Patients with positive titers for autoimmune antibodies are allowed on the study in the absence of history of clinical manifestations of autoimmune disease. * Patients must not have conditions of immunosuppression or chronic requirement for treatment with systemic steroids, including oral steroids, continuous use of topical steroid creams or ointments, or any inhaled steroid containing inhalers. Patients who discontinue use of these classes of medication for at least 2 weeks are eligible. Treatment with steroids or other immunosuppressant medications is allowed during the study if clinically required to treat side effects related to autoimmunity that may develop secondary to the study agents. * Patients must be free of brain metastasis by contrast-enhanced CT/MRI scans within 4 weeks prior to starting the study drugs. If known to have prior brain metastases, must not have evidence of active brain disease on two successive MRI evaluations at least 3 months apart (one of which is £ 4 weeks prior to starting the study drugs). * Female patients of child bearing potential must have a negative pregnancy test, and must not be breast feeding. * Patients must agree to use effective contraception (both males and females).
Exclusion criteria
* Serious illnesses, such as: cardiovascular disease (uncontrolled congestive heart failure, hypertension, cardiac ischemia, myocardial infarction, severe cardiac arrhythmia), bleeding disorders, autoimmune diseases, severe obstructive or restrictive pulmonary diseases, active systemic infections, and inflammatory bowel disorders. * Treatment with mitomycin C or nitrosureas within six weeks prior to study entry. * Any significant psychiatric disease, medical intervention, or other condition, which in the opinion of the principal investigator, could prevent adequate informed consent or compromise participation in the clinical trial. * Active infection or antibiotics within one-week prior to study, including unexplained fever (temp \> 38.1°C). * Treatment with anticoagulants, except to keep an indwelling line patent. * Systemic steroid or other immunosuppressive therapy within 4 weeks of starting the study. * Treatment with any investigational product within 28 days of registration. * History of inflammatory bowel disease (e.g. Crohn's disease or ulcerative colitis), celiac disease, or other chronic gastrointestinal conditions associated with diarrhea, or current acute colitis of any origin, or any history of diverticulitis (even a single episode) or evidence of diverticulitis at baseline, including evidence limited to CT-scan only. * Patients who did not tolerate high-dose interferon-α therapy in the adjuvant setting will be excluded.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Best Objective Response Rate (BORR) | Up to 44 months | Intention to treat response rate is estimated by the proportion of patients with a best response of CR, PR, or SD by Response Evaluation Criteria in Solid Tumors \[RECIST\] version 1.0 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free Survival (PFS) | Up to 44 months | Time from initial treatment date of to date of documented progression of disease progression (TTP) |
| 1-year Overall Survival (OS) | Time from initial treatment date, up to 1 year | 1-year survival is the estimated probability of surviving one year expressed as a percent (probability of survival is not probability of dying). |
| Median Overall Survival (Point Estimate) | Up to 44 months | Median overall survival is the (point) estimate of the time corresponding to 50% estimated probability of survival. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Interferon Alfa-2b + Tremelimumab Patients treated with Tremelimumab 15 mg/kg at start of C1 + IFN-2b IV 20 MU/m2/d for 5 d/wk for 4 weeks; C2 onward- IFN-2b SQ 10MU/m2/d for 3 d/wk for 4 weeks | 37 |
| Total | 37 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Not evaluable for response | 2 |
Baseline characteristics
| Characteristic | Interferon Alfa-2b + Tremelimumab |
|---|---|
| Age, Continuous | 56 years |
| Sex: Female, Male Female | 14 Participants |
| Sex: Female, Male Male | 23 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 37 / 37 |
| serious Total, serious adverse events | 15 / 37 |
Outcome results
Primary
Best Objective Response Rate (BORR)
Intention to treat response rate is estimated by the proportion of patients with a best response of CR, PR, or SD by Response Evaluation Criteria in Solid Tumors \[RECIST\] version 1.0
Time frame: Up to 44 months
Population: Patients treated with Tremelimumab 15 mg/kg at start of C1 + IFN-2b IV 20 MU/m2/d for 5 d/wk for 4 weeks; C2 onward- IFN-2b SQ 10MU/m2/d for 3 d/wk for 4 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Interferon Alfa-2b + Tremelimumab | Best Objective Response Rate (BORR) | 24 percentage of patients |
Secondary
1-year Overall Survival (OS)
1-year survival is the estimated probability of surviving one year expressed as a percent (probability of survival is not probability of dying).
Time frame: Time from initial treatment date, up to 1 year
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Interferon Alfa-2b + Tremelimumab | 1-year Overall Survival (OS) | 62 percentage of patients |
Secondary
Median Overall Survival (Point Estimate)
Median overall survival is the (point) estimate of the time corresponding to 50% estimated probability of survival.
Time frame: Up to 44 months
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Interferon Alfa-2b + Tremelimumab | Median Overall Survival (Point Estimate) | 21 months |
Secondary
Progression-free Survival (PFS)
Time from initial treatment date of to date of documented progression of disease progression (TTP)
Time frame: Up to 44 months
Population: Patients with stage IV melanoma (cutaneous, uveal, or mucosal) and measurable disease, most who had previously received therapy
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Interferon Alfa-2b + Tremelimumab | Progression-free Survival (PFS) | 6.4 months |